看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
( T) r# p3 \" v4 y1 }$ u- j+ J4 W
1 i- I" [. {& u k" i" k- y0 Z! [7 @ ]7 C. S
Currently available feasibility data for possible combination strategies. & s2 H! H) Q) y3 W! f
————————————————————————————————! @/ e3 \# |% Z3 U2 \
Combination Feasibility according to preliminary data
6 u$ y/ N6 Y: C3 ~. N——————————————————————————————————, {. @- b3 m0 W
Bevacizumab + sorafenib Yes, reduced dose
% }: z7 X, C2 s9 DBevacizumab + sunitinib† No
& m% @0 ]0 f1 J8 `Bevacizumab + temsirolimus Yes
& q& I: q# W# _$ ], G: H) {+ wBevacizumab + everolimus Yes
! l, i' |+ z& F( l: h" d. XSorafenib + sunitinib ?
- `% }* w0 ^3 t% p' E. e( j: E. dSorafenib + temsirolimus Yes, reduced dose
: \2 x4 n+ q5 {7 l5 d. L* dSorafenib + everolimus Yes, reduced dose & f4 F, ?- T4 Y" P$ o! a7 S# f
Sunitinib + temsirolimus† No
/ @7 e7 c/ r S N/ aSunitinib + everolimus ?
% l R" K; A; {6 G4 N! z/ TTemsirolimus + everolimus ?
! u1 \* k* L! o& t. Z4 Q————————————————————* P9 u$ v# _- X. J
†Led to US FDA warning.( F% ^5 ?: D) v& U( j" U- v
?: As yet unattempted combination.8 O( Z8 v7 V: e
|